Pearls aid treatment of opioid dependence
By Jessica Berthold
A 32-year-old woman presents to your primary care office requesting treatment for heroin addiction. She was treated at the hospital six months ago for a heroin overdose but has been using the opioid ever since. What do you do to help her?
Agonist treatment, with either methadone or buprenorphine, is your best option, said Jeffrey Samet, FACP, at an Internal Medicine 2010 session on illicit drugs that focused mainly on opioid abuse. The two treatments work equally well, he said.
Jeffrey Samet, FACP
“To simply go out and stop using doesn’t work that well. We wish it did, but there is a low rate of retention in treatment, and achievement of abstinence, for people who just try to detox and stop,” said Dr. Samet, chief of general internal medicine at Boston Medical Center and Boston University School of Medicine. “That’s why there is a big push to get people into opioid agonist treatment.”
Indeed, fewer than half of those who try to quit opioids cold turkey stay abstinent at six months, and fewer than 20% are abstinent at 12 months, he said.
The goal of maintenance agonist treatment is to create a sort of “narcotic blockade” that alleviates cravings for the drug. “You begin to normalize the deranged brain changes and deranged physiology (from addiction),” Dr. Samet said.
Patients need to be aware, however, that they may experience a state of chronic opioid withdrawal, even if they are taking agonists, that can last months or years. Symptoms include malaise, fatigue, poor tolerance to stress and pain, restlessness, cravings and insomnia.
“This can be a real problem for which you can tell your patient that, over time—months or years sometimes—these symptoms do tend to get better,” Dr. Samet said.
Methadone maintenance therapy has many years of proven efficacy, he said.
“There’s lots of data out there showing methadone increases overall survival, treatment retention, and employment. It decreases illicit opioid use, criminal activity and hepatitis/HIV seroconversion, and it improves birth outcomes,” he said. “So it’s not perfect, but it is very helpful in terms of outcomes.”
Maintenance treatment is highly structured, and typically operates outside the standard medical world, through separate clinics. It involves daily dosing, daily nursing assessments, weekly individual and/or group counseling, random supervised urine screens, psychiatric services, and sometimes medical services.
“Individuals can eventually earn ‘take-home’ doses, if they have met the goals of the program long enough, so they don’t have to come in every day,” Dr. Samet said. “It can be fun to ask patients whether they are getting take-homes, because it shows them you know something about opioid treatment.”
Limitations of methadone treatment include limited access, depending on where patients live. Five states have no methadone clinics at all, while four states have fewer than three, he said. For those that do have access, patients often view the treatment as inconvenient and highly punitive, because they must go in every day to get medicine, he added.
Other problems are the clinics’ mix of stable and unstable patients, which can trigger relapses; lack of privacy; and the stigma against methadone use among physicians, peers and family. “Also, to a certain extent, there is little ability to ‘graduate’ the program,” he said. “You are in the program for long periods of time.”
Buprenorphine plus naloxone
Buprenorphine has been shown in randomized controlled trials to be just as effective as moderate doses (80 mg) of methadone in terms of abstinence, treatment retention and decreased cravings, Dr. Samet said.
“If you ask me which is better (buprenorphine or methadone), I’d say they are both very useful,” Dr. Samet said. “I like them both, they both help, and it depends on the situation the patient is in. If the patient needs structure, methadone might be a good choice. But clearly, buprenorphine is easier, from a patient’s perspective.”
A schedule III drug in the form of sublingual tablets, buprenorphine is typically taken with naloxone (combination trade name: Suboxone, Reckitt Benckiser Pharmaceuticals). When taken sublingually, naloxone isn’t absorbed.
“So why is it there? Well, if you’ve been in the business of pain medication addiction, you know that everything that is given orally gets abused by some other route. So if you try to take Suboxone intravenously, you won’t be happy … it will put you into acute withdrawal, because the naloxone is absorbed if given intravenously” he said.
Suboxone, for which the typical maximum dose is 16 mg per day, also has high receptor affinity, slow dissociation and a ceiling effect for respiratory depression but not analgesia, he said. It should be given to patients while they are withdrawing.
“Otherwise, since it’s a partial agonist and not a full agonist like methadone, and since it has strong receptor affinity, it will bump off full agonists from the receptor and put the person into withdrawal. So if they come when withdrawing, [Suboxone] helps them stop withdrawing, and it’s a fairly smooth transition,” he said.
Whether patients are taking Suboxone or methadone, Narcotics Anonymous can be a useful adjunct, as can outpatient counseling, Dr. Samet added.
Treating in the hospital
What if, while you’re treating a patient in the hospital, she claims she’s going through heroin withdrawal and requests treatment? How do you know if she’s telling the truth?
Check out her pupils, Dr. Samet said.
“Dilated pupils can’t be faked,” he said, while other symptoms of withdrawal can be seen in the hospital for a host of reasons: nausea, restlessness, a heart rate above 100 beats/min, abdominal cramps, sweating, runny nose and watery eyes.
When verified, withdrawal should be promptly treated. Not addressing it can prevent fully dealing with any other medical/surgical condition the patient has. In other words, this is not the time to make the patient go cold turkey.
“Withholding opioids will not cure the patient’s addiction, and giving opioids won’t worsen the addiction,” Dr. Samet said. “You can’t expect to cure the dependence during this hospital stay.”
Methadone is the best treatment choice for opioid-addicted inpatients, he said. It’s available in tablets, as an oral solution and parenterally; has an onset time of 30 to 60 minutes; and lasts about 6 hours for pain and 24 hours in preventing withdrawal.
Start with a 20-mg dose (“People don’t stop breathing with this amount,” Dr. Samet said) and reassess every two to three hours, giving an additional 5 to 10 mg until withdrawal signs abate.
“Again, rely on the pupils to gauge withdrawal,” Dr. Samet said.
Be sure not to exceed 40 mg of methadone in 24 hours, and monitor the patient for central nervous system and respiratory depression. On the following day, give the patient the same total dose you gave in the previous 24 hours.
“Remember, the goal is to alleviate acute withdrawal; the patient will continue to crave heroin,” Dr. Samet said.
If the patient’s drug test is positive for opiates on the second day of hospitalization, it is not the result of the methadone, he added; as a synthetic opioid, methadone won’t show up. The results probably can be explained by residual heroin from before the patient’s admission; any morphine the patient was given after admission; illicit opioid use during hospitalization (for example, if the patient left the floor to use); or even ingestion of a poppyseed bagel.
Once the patient has had her acute withdrawal symptoms relieved, you can proceed to the long-term treatment options outlined previously. Be aware, however, that patients are at the greatest risk of overdose if they go back to using within the first 12 months after a quit attempt, because their tolerance is low, Dr. Samet said.
Internist Archives Quick Links
Internal Medicine Meeting Early Registration Discount
Register early for Internal Medicine Meeting 2015 in Boston, MA to lock in the lowest possible rate. Learn more or register now!
Are You Using ACP Smart Medicine®?
This online clinical decision support tool is a FREE benefit of ACP membership delivering point-of-care access to evidence-based recommendations. Includes more than 500 modules, images and reference tables. Start now or watch the video tour.